BeiGene, Ltd. (BGNE): Price and Financial Metrics


BeiGene, Ltd. (BGNE): $122.99

-12.18 (-9.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BGNE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BGNE POWR Grades


  • BGNE scores best on the Value dimension, with a Value rank ahead of 70.41% of US stocks.
  • BGNE's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • BGNE ranks lowest in Momentum; there it ranks in the 4th percentile.

BGNE Stock Summary

  • With a market capitalization of $21,330,946,597, BeiGene Ltd has a greater market value than 88.24% of US stocks.
  • BGNE's price/sales ratio is 18.13; that's higher than the P/S ratio of 92.21% of US stocks.
  • As for revenue growth, note that BGNE's revenue has grown 280.83% over the past 12 months; that beats the revenue growth of 97.02% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to BeiGene Ltd, a group of peers worth examining would be QRVO, SGEN, BLDP, RDCM, and CYTK.
  • Visit BGNE's SEC page to see the company's official filings. To visit the company's web site, go to www.beigene.com.

BGNE Valuation Summary

  • In comparison to the median Healthcare stock, BGNE's EV/EBIT ratio is 171.33% lower, now standing at -20.9.
  • BGNE's price/sales ratio has moved down 35.8 over the prior 68 months.
  • BGNE's price/sales ratio has moved down 35.8 over the prior 68 months.

Below are key valuation metrics over time for BGNE.

Stock Date P/S P/B P/E EV/EBIT
BGNE 2021-08-31 30.3 8.0 -21.9 -20.9
BGNE 2021-08-30 29.7 7.8 -21.4 -20.5
BGNE 2021-08-27 27.7 7.3 -20.0 -19.1
BGNE 2021-08-26 27.8 7.3 -20.1 -19.1
BGNE 2021-08-25 28.5 7.5 -20.6 -19.6
BGNE 2021-08-24 28.1 7.4 -20.3 -19.3

BGNE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BGNE has a Quality Grade of C, ranking ahead of 25.08% of graded US stocks.
  • BGNE's asset turnover comes in at 0.168 -- ranking 211th of 681 Pharmaceutical Products stocks.
  • AADI, CPIX, and NAVB are the stocks whose asset turnover ratios are most correlated with BGNE.

The table below shows BGNE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.168 0.883 -0.377
2021-03-31 0.165 0.897 -0.358
2020-12-31 0.065 0.771 -0.552
2020-09-30 0.070 0.746 -0.678
2020-06-30 0.078 0.704 -0.890
2020-03-31 0.166 0.826 -0.893

BGNE Stock Price Chart Interactive Chart >

Price chart for BGNE

BGNE Price/Volume Stats

Current price $122.99 52-week high $426.56
Prev. close $135.17 52-week low $118.18
Day low $118.18 Volume 300,000
Day high $132.00 Avg. volume 314,169
50-day MA $169.46 Dividend yield N/A
200-day MA $265.21 Market Cap 12.63B

BeiGene, Ltd. (BGNE) Company Bio


BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People’s Republic of China. The company was founded in 2010 and is based in the Cayman Islands.


BGNE Latest News Stream


Event/Time News Detail
Loading, please wait...

BGNE Latest Social Stream


Loading social stream, please wait...

View Full BGNE Social Stream

Latest BGNE News From Around the Web

Below are the latest news stories about BeiGene Ltd that investors may wish to consider to help them evaluate BGNE as an investment opportunity.

BeiGene''s Brukinsa Applications Under FDA, European Review For Leukemia

The European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd''s (NASDAQ: BGNE ) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). In November 2021, Brukinsa received its

Benzinga | February 22, 2022

BeiGene''s Brukinsa gets FDA review for expanded use in blood cancer subtype

The U.S. Food and Drug Administration ((FDA)) accepted BeiGene''s (BGNE) application seeking approval of Brukinsa (zanubrutinib) to treat adult patients with chronic lymphocytic

Seeking Alpha | February 22, 2022

BeiGene's Brukinsa Applications Under FDA, European Review For Leukemia

The European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). In November 2021, Brukinsa received its first approval in the European Union (EU) for Waldenström's macroglobulinemia (WM), who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy. Additionally, the FDA has als

Yahoo | February 22, 2022

BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma

BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING, February 22, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the European Medicines Agency (EMA) has accepted for review two new indication applications for its BTK inhibitor BRUKINSA® (zanubrutinib) for the treatment of patients with chronic lymphocyt

Yahoo | February 22, 2022

BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

CAMBRIDGE, Mass. and BEIJING, February 22, 2022--BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

Yahoo | February 22, 2022

Read More 'BGNE' Stories Here

BGNE Price Returns

1-mo -24.45%
3-mo -43.02%
6-mo -64.63%
1-year -64.90%
3-year -2.86%
5-year 228.67%
YTD -54.60%
2021 4.85%
2020 55.88%
2019 18.18%
2018 43.53%
2017 221.87%

Continue Researching BGNE

Want to see what other sources are saying about BeiGene Ltd's financials and stock price? Try the links below:

BeiGene Ltd (BGNE) Stock Price | Nasdaq
BeiGene Ltd (BGNE) Stock Quote, History and News - Yahoo Finance
BeiGene Ltd (BGNE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5294 seconds.